IGF-1 DES
Des(1-3)IGF-1 — Truncated IGF-1 Analog
What is IGF-1 DES?
IGF-1 DES (Des(1-3)IGF-1) is a naturally occurring truncated form of IGF-1 that lacks the first three amino acids of the N-terminus. This modification dramatically reduces binding to IGF-binding proteins (IGFBPs) — even more so than IGF-1 LR3 — making it significantly more potent per molecule. However, its short half-life means it acts locally at the injection site rather than systemically.
By having essentially no IGFBP binding, IGF-1 DES is immediately bioavailable to local tissue receptors. Its short half-life means it is rapidly cleared but acts intensely at the injection site. This local action is exploited in site-specific injection protocols — injecting directly into lagging muscle groups to preferentially stimulate local IGF-1 receptor signaling and hypertrophy in that site.
Research Evidence
IGF-1 DES is approximately 10x more potent per unit than standard IGF-1 in vitro due to near-zero IGFBP binding. Established in in vitro and animal research.
Community use for site-specific muscle growth based on local injection mechanism. No controlled human trials. Mechanism is plausible based on local IGF-1 receptor binding.
Evidence grades: Gold = RCT human data · Silver = consistent animal/human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 1 mg | 2 ml | 500 mcg/ml | 50mcg = 10 units |
| 1 mg | 1 ml | 1 mg/ml | 50mcg = 5 units |
Frequently Asked Questions
What is the difference between IGF-1 DES and IGF-1 LR3?
IGF-1 LR3 has a 20-30 hour half-life and acts systemically across all tissues. IGF-1 DES has a ~20-30 minute half-life and acts locally at the injection site. LR3 for systemic anabolism; DES for site-specific hypertrophy. They can be used together on training days.
Is IGF-1 DES more potent than IGF-1 LR3?
Per molecule, yes — approximately 10x more potent due to minimal IGFBP binding. However, the short half-life limits systemic exposure. For systemic anabolic effects, IGF-1 LR3 is more practical. For local site-specific effects, IGF-1 DES is theoretically superior.
References
- [1]Ballard FJ, Ross M, Upton FM, Wallace JC. Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively. Biochem J. 1987;249(3):721-726.
- [2]Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article